|Previous Section||Index||Home Page|
The IC is looking, with the Department and other stakeholders at the way forward. The funding requirements will be dependent on the outcome of these discussions and will feed into relevant organisations business planning for 2008-09 and subsequent years. We cannot yet predict when the results of the survey will be published.
Mr. Spring: To ask the Secretary of State for Health how many patients were admitted to (a) West Suffolk hospital, (b) Addenbrookes hospital and (c) Ipswich hospital as a consequence of (i) alcoholic liver disease and (ii) cirrhosis in each of the last five years. 
Mr. Ivan Lewis: Information is not available by individual hospital rather it is collected for national health service trusts that the named hospitals are managed by. The following table shows the count of finished admission episodes at West Suffolk Hospital, Cambridge University Hospital National Health Service Foundation Trust (of which Addenbrookes Hospital is a part), and Ipswich Hospital.
|Count of finished admission episodes where alcoholic liver disease (K70) or cirrhosis of the liver (K703, K717, K743, K744, K745, K746) were mentioned in any primary or secondary diagnosis field for selected trusts|
|Cambridge University Hospital NHS Foundation Trust (RGT)( *)||Ipswich Hospital NHS Trust (RGQ)*||West Suffolk NHS Trust (RGR)*|
|Alcoholic liver disease||Cirrhosis of the liver||Alcoholic liver disease||Cirrhosis of the liver||Alcoholic liver disease||Cirrhosis of the liver|
1. All diagnosis count of episodes: These figures represent a count of all finished admission episodes where the diagnosis was mentioned in any of the 14 (7 prior to 2002-03 diagnosis field in a HES record).
2. ICD10 code used for Alcoholic Liver Disease = K70
ICD10 codes used for Cirrhosis of Liver:
K70.3 Alcoholic cirrhosis of liver
K71.7 Toxic liver disease with fibrosis and cirrhosis of liver
K74.3 Primary biliary cirrhosis
K74.4 Secondary biliary cirrhosis
K74.5 Biliary cirrhosis, unspecified
K74.6 other and unspecified cirrhosis of liver
Code K70.3 is also included within the data for alcoholic liver disease. Do not add these figures together as this would cause double counting.
3. Assessing growth through time: HES figures are available from 1989-90 onwards. During the years that these records have been collected in the NHS there have been ongoing improvements in quality and coverage. These improvements in information submitted by the NHS have been particularly marked in the earlier years and need to be borne in mind when analysing time series. Changes in NHS practice also need to be borne in mind when analysing times series. For example a number of procedures may now be undertaken in outpatient settings and may no longer be accounted in the HES data. This may account for any reductions in activity over time.
4. Data Quality: HES are compiled from data sent by over 300 NHS trusts and primary care trusts (PCTs) in England. The Information Centre for health and social care liaises closely with these organisations to encourage submission of complete and valid data and seeks to minimise inaccuracies and the effect of missing and invalid data via HES processes. While this brings about improvement over time, some shortcomings remain.
5. Finished admission episodes: A finished admission episode is the first period of in-patient care under one consultant within one health care provider. Admissions do not represent the number of in-patients, as a person may have more than one admission within the year.
6. Ungrossed Data: Figures have not been adjusted for shortfalls in data (i.e. the data are ungrossed).
Hospital Episode Statistics (HES, The Information Centre for health and social care
Mr. Lansley: To ask the Secretary of State for Health what the (a) start and (b) end date is of each activity he has planned for next year to tackle excessive alcohol consumption; and what the expected cost is of each activity in each year for which expenditure is planned. 
Dawn Primarolo: The start and end dates of planned activity to tackle excessive alcohol consumption next year are listed and described in detail with timescales in Annex B in The Governments renewed alcohol strategy, Safe. Sensible. Social, published in June 2007. A copy is available in the Library.
The Department is spending £1.7 million in 2006-07 on the Know your Limits campaign, which is a joint campaign with the Home Office who are contributing additional funding. In the case of the NHS, primary care trusts are responsible for delivering improvements to patient care, so spending on activity outlined in the strategy will be based on local decisions. We would also expect there to be scope for off-setting efficiency savings, for example from reduced hospital admissions.
Mr. Stephen O'Brien: To ask the Secretary of State for Health what the expenditure by (a) his Departments research and development budget and (b) the Medical Research Council on research into rheumatoid arthritis was in each year since 1997-98. 
Implementation of the Departments research strategy Best Research for Best Health has led to an expansion of our research programmes and in significant new funding opportunities for health research. Work relevant to rheumatoid arthritis will for example be undertaken in several of the National Institute for Health Research Biomedical Research Centres (BRC). The Cambridge BRC has a musculoskeletal disorders research theme to which £2.2 million has been allocated over five years; and the Imperial College Healthcare NHS Trust BRC has a rheumatology research theme for which the total budget over five years is £2.7 million.
The Medical Research Council (MRC) is one of the main agencies through which the Government supports biomedical research. The MRC is an independent body funded by the Department for Innovation, Universities and Skills.
The MRC funds a large portfolio of research related to arthritis and rheumatism much of which will be of
relevance to rheumatoid arthritis. Available MRC expenditure figures for research relevant to arthritis and rheumatism are shown in the following table.
|Expenditure (£ million)|
Mr. Stephen O'Brien: To ask the Secretary of State for Health how many drugs for the treatment of rheumatoid arthritis were dispensed in the community in each year since 1997; and at what net ingredient cost. 
Dawn Primarolo: The main drugs that can be used to treat rheumatoid arthritis are listed at paragraphs 10.1.1 (Non-steroidal anti-inflammatory drugs), 10.1.2 (Corticosteroids) and 10.1.3 (Rheumatic disease suppressant drugs) of the British National Formulary (BNF). The number of prescription items dispensed and associated net ingredient cost for drugs listed in these paragraphs are shown in the following tables. Some prescribing of these drugs will be for reasons other than rheumatoid arthritis (e.g. muscle strain) and there will be some prescribing from other areas of the BNF for the condition, e.g. BNF section 4.7 (Analgesics), which is not included.
|Prescription items dispen sed in the community, in England|
|BNF paragraph 10.1.1||BNF paragraph 10.1.2||BNF paragraph 10.1.3||Total|
Prescription cost analysis (PCA) system
|Net ingredient cost of prescription items dispensed in the community, in Engla nd|
|BNF paragraph 10.1.1||BNF paragraph 10.1.2||BNF paragraph 10.1.3||Total|
|Next Section||Index||Home Page|